Logo

Takeda Renews Deal with Proteome Sciences

Mar 30, 2011

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Proteome Sciences today announced Takeda Pharmaceuticals has extended a contract to use PS Biomarker Services for the development of mass spectrometry-based assays for disease-related proteins.

Financial and other terms of the deal were not disclosed.

In a statement, Proteome Sciences said it will apply its capabilities in the discovery and validation of peptide and protein biomarkers and in assay development for research covered by the deal.

The firms originally partnered in 2009 to use the PS Biomarker Services and Proteome Sciences' isobaric Tandem Mass Tags for a preclinical study.

Filed under

Research Funding
Proteomics & Protein Research
Mass Spec
Biomarker Discovery & Validation
research alliance
proteomics
biomarker discovery
Takeda
Proteome Sciences
Breaking News
The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.